Alex Ranahan

Alex Ranahan asked about specific adverse events or metrics to monitor for ALK7 or direct Activin E modulators that WVE-007's INHBE targeting strategy might avoid, and how WVE-007's duration of mass benefit could address comorbid conditions.

Answer

President and CEO Paul B. Bolno stated that WVE-007 exhibits a distinct safety and efficacy profile, particularly in fat loss, compared to other myostatin and activin pathways. He noted the need to observe the long-term downstream impacts of multifaceted ligand strategies like ALK7. Bolno emphasized that WVE-007's specificity, established through human genetics and clinical studies, is a key differentiator. He highlighted that a 5% or more reduction in visceral fat, which WVE-007 has surpassed, is well-established to improve cardiovascular and diabetic outcomes. The profile of substantial fat reduction, lean mass preservation, and once-to-twice-a-year dosing positions WVE-007 as an optimal therapy for health outcomes and has the potential to significantly expand the global obesity treatment landscape.

Alex Ranahan asked about specific adverse events or metrics to monitor for ALK7 or direct Activin E modulators that WVE-007's INHBE targeting might avoid, and how WVE-007's duration of mass benefit could address comorbid conditions.

Answer

Paul Bolno, President and CEO, noted WVE-007's differentiated safety and efficacy profile, particularly in fat loss, compared to other myostatin/activin pathways. He emphasized INHBE's specificity over ALK7, which signals via multiple ligands, reducing unintended consequences. Bolno highlighted that a 5% or more reduction in visceral fat, which WVE-007 surpassed with nearly 10% reduction at the lowest dose, is well-established to improve cardiovascular and diabetic outcomes. The once-to-twice-a-year dosing with muscle preservation offers a significant advantage for long-term health outcomes and market access.